Loading
SB
Sienna Biopharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by ARCH Venture Partners VIII, LLC, was filed 26 Feb 2019.
Sienna Biopharmaceuticals, Inc.: what insiders have been doing
Sienna Biopharmaceuticals, Inc. is a listed company. Its directors and officers file their transactions with SEC (Form 4). Sienna Biopharmaceuticals, Inc. has had no insider filing for more than a year; the last one goes back to 4 October 2019.
Our records for Sienna Biopharmaceuticals, Inc. go back to 2017, with 16 purchases and 16 sales on the open market in total.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
69
Thresholds
n/a
Buy Volume
€15M
16 ops. · all time
Sell Volume
€1M
16 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2018FY ended December 2018 · cache
Income statement
Net income-65.5M
Last declaration on 4 October 2019
Declarations69 total
2,396 shares@ US$0.2332.5% of flowCommon StockSEC:0001562180-19-005117:0
55,000 sharesCommon StockSEC:0001562180-19-004217:0
50,000 sharesCommon StockSEC:0001562180-19-004219:0
70,000 sharesCommon StockSEC:0001562180-19-004218:0
150,000 sharesCommon StockSEC:0001562180-19-004216:0
4,095 shares@ US$0.76100.0% of flowCommon StockSEC:0001562180-19-003852:0
4,095 shares@ US$0.76100.0% of flowCommon StockSEC:0001562180-19-003850:0
4,095 shares@ US$0.76100.0% of flowCommon StockSEC:0001562180-19-003851:0
17,063 shares@ US$0.7611.5% of flowCommon StockSEC:0001562180-19-003848:0
1,552 shares@ US$0.7667.5% of flowCommon StockSEC:0001562180-19-003849:0
20,000 sharesCommon StockSEC:0001562180-19-002196:0
150,000 shares@ US$2.507.4% of flowCommon StockSEC:0001012975-19-000197:0
Canonical exit: 23 May 2019 (T+90)
1,865,800 shares@ US$2.5092.6% of flowCommon StockSEC:0001012975-19-000198:2
Canonical exit: 23 May 2019 (T+90)
150,000 shares@ US$2.507.4% of flowCommon StockSEC:0001012975-19-000198:0
Canonical exit: 23 May 2019 (T+90)
150,000 shares@ US$2.507.4% of flowCommon StockSEC:0001012975-19-000199:0
Canonical exit: 23 May 2019 (T+90)
1,865,800 shares@ US$2.5092.6% of flowCommon StockSEC:0001012975-19-000199:2
Canonical exit: 23 May 2019 (T+90)
1,865,800 shares@ US$2.5092.6% of flowCommon StockSEC:0001012975-19-000197:2
Canonical exit: 23 May 2019 (T+90)
100,000 shares@ US$2.50100.0% of flowCommon StockSEC:0001562180-19-001423:0
Canonical exit: 23 May 2019 (T+90)
100,000 shares@ US$2.50100.0% of flowCommon StockSEC:0001562180-19-001424:0
Canonical exit: 23 May 2019 (T+90)
40,000 shares@ US$2.5088.5% of flowCommon StockSEC:0001562180-19-001422:0
Canonical exit: 23 May 2019 (T+90)
45,000 sharesCommon StockSEC:0001562180-19-000147:0
187,500 sharesCommon StockSEC:0001562180-19-000146:0
45,000 sharesCommon StockSEC:0001562180-19-000148:0
45,000 sharesCommon StockSEC:0001562180-19-000150:0
45,000 sharesCommon StockSEC:0001562180-19-000149:0
25 of 69 declarations
About Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for skin diseases. It is listed on NASDAQ under the ticker SNNA.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
